Axsome Q1 net product revenue $75M (+160% YoY); net loss $68.4M; pipeline milestones on track

Axsome Therapeutics, Inc.

2024-Q1 EPS reported -$1.44 revenue$74,999,000

Auvelity net sales $53.4M (+240% YoY); Sunosi net revenue $21.6M (+64% YoY).
Net loss $68.4M ($1.44/diluted share) vs $11.2M loss in Q1 2023 which included $62M one-time gain.
Cash $331.4M at March 31, 2024; company expects funds to support operations into cash flow positivity.
NDA resubmission for AXS-07 in migraine and NDA submission for AXS-14 in fibromyalgia targeted for Q2 2024.
Positive Phase 3 SYMPHONY trial of AXS-12 in narcolepsy; Phase 3 ACCORD-2 for AXS-05 in Alzheimer's agitation initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.

Period: first quarter of 2024
Revenue: $75.0 million
Net income: $68.4 million
EPS: $(1.44) per share
Result: reported results

Exact text from the filing

Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.